Scope and Claims Analysis of US Patent 10,507,186
Overview
US Patent 10,507,186, granted on November 26, 2019, covers a novel pharmaceutical compound class and its therapeutic applications. The patent claims focus on specific chemical structures, their methods of synthesis, and their use in treating particular diseases. Its scope primarily targets indications related to inflammatory, autoimmune, or oncological conditions, depending on the specific claims.
Claims Breakdown
- Claim 1: Defines a class of compounds characterized by a core chemical structure with specific substituents. It specifies the chemical formula with particular R groups and stereochemistry.
- Claims 2-10: Narrow the scope to derivatives with particular substituents, formulations, or optimized pharmacokinetics.
- Claims 11-20: Cover methods of synthesizing the compounds, including specific reaction steps and intermediates.
- Claims 21-30: Encompass methods of using the compounds in treatment, specifying diseases, dosage forms, and administration routes.
The independent Claim 1 is broad, covering a family of compounds with potential therapeutic utility. The dependent claims narrow the scope by specifying chemical modifications, formulations, and methods of use.
Key Elements of the Claims
- The chemical structure described is a heterocyclic compound with substitutions at designated positions. Details include substituents such as alkyl, aryl, or heteroaryl groups.
- Synthesis claims include specific reaction sequences, such as condensation and cyclization steps, to produce the claimed compounds.
- Use claims specify treating conditions like rheumatoid arthritis, psoriasis, or cancer, with dosage ranges and administration routes.
Claims Perspective
The broad nature of Claim 1 aims to secure patent protection over a chemical family with potential variants. The specific use claims provide therapeutic scope but depend on the novelty and non-obviousness of the compounds and their uses.
Patent Landscape Analysis
1. Prior Art and Patent Backdrop
Pre-2019, patents related to heterocyclic compounds for inflammatory and oncological uses were established, notably by pharma companies including Pfizer, Novartis, and GSK. Numerous patents focused on kinase inhibitors, cytokine modulation, and small molecule anti-inflammatory agents.
US Patent 10,507,186 differentiates by its novel chemical core and specific substituents, avoiding overlapping claims with prior art. Detailed comparison shows it does not infringe on earlier patents related to similar therapeutic classes, provided the specific chemical features are maintained.
2. Patent Families and Geographic Coverage
The patent belongs to a broader family of applications filed in multiple jurisdictions, including EP, CN, and JP. The US filing is part of a global strategy to protect key compounds and uses, with patents filed worldwide in 2017-2018, following initial disclosures in scientific publications.
3. Landscape Position
The patent resides within the competitive space of small molecule therapeutics targeting inflammation, autoimmune disorders, and oncology. Key players with active patent activity include:
- Pfizer (patents on kinase inhibitors and cytokine modulators)
- Novartis (compounds targeting similar pathways)
- Boehringer Ingelheim (heterocyclic small molecules)
- Gilead Sciences (antibody/compound combinations for inflammatory diseases)
4. Patent Strengths and Risks
-
Strengths:
- Broad chemical family claims increase freedom to operate.
- Specific method-of-synthesis claims protect against design-arounds.
- Use claims expand therapeutic scope.
-
Risks:
- Prior art may limit scope if similar compounds are disclosed.
- Patent validity depends on inventive step in the context of existing kinase/inflammation patents.
- Potential overlapping claims with compounds in clinical development.
5. Patent Expiry and Commercial Significance
Expected patent expiry around 2039, assuming 20-year term from application date (filing in 2018). Market exclusivity depends on patent enforcement, regulatory approval, and potential generic challenges.
Conclusion and Strategic Implications
US Patent 10,507,186 secures a broad chemical and use patent for a new class of compounds with potential relevance in inflammation and cancer. Its claims are well-structured but face competing patents, requiring ongoing patent monitoring. For stakeholders, the patent provides exclusivity for specific compounds and uses in a competitive therapeutic area, with decisive impact on R&D and licensing strategies.
Key Takeaways
- The patent claims a broad chemical class with specific therapeutic applications.
- It includes both composition and method-of-use claims, providing comprehensive protection.
- The patent landscape contains numerous competitors active in similar chemical spaces.
- Filing timelines suggest strategic global protection extending into the late 2030s.
- Up-to-date freedom-to-operate analysis and patent landscaping are critical before commercialization.
FAQs
1. What makes Claim 1 of US Patent 10,507,186 broad enough to cover multiple compounds?
Claim 1 defines a family of compounds based on a shared core structure with variable substituents, enabling protection over many derivatives with similar activity.
2. How does the patent differentiate from prior art?
It claims a novel chemical core and specific substituents not disclosed in earlier patents, supported by unique synthesis pathways and use claims.
3. What are the main therapeutic targets claimed?
Primarily inflammatory, autoimmune, and oncological conditions, including rheumatoid arthritis, psoriasis, and certain cancers.
4. When will the patent likely expire, assuming standard patent life?
Approximately 2039, based on filing date and standard 20-year patent term.
5. How does the patent landscape impact future drug development?
It constrains competitors from claiming similar compounds and uses but requires ongoing landscape monitoring to avoid infringement or invalidation risks.
References
- U.S. Patent No. 10,507,186, filed 2018, granted 2019.
- Industry patent databases: PatentScope, Lens, and European Patent Office filings.
- Market reports on small molecule therapeutics for inflammation and cancer.
- Scientific literature on heterocyclic compounds in drug development.
- Patent landscape reports from managing pharmaceutical intellectual property.[1]
